Table 9 Dysregulation of CDK3 in clinical samples
From: A review on the role of cyclin dependent kinases in cancers
Tumor type | Samples | Expression (Tumor vs. Normal) | Kaplan–Meier analysis (impact of regulators dysregulation) | Multivariate Cox regression analysis | Association of dysregulation of regulators with clinicopathologic characteristics | References |
|---|---|---|---|---|---|---|
Breast cancer | 37 cases of lymph node metastatic BC tissues, and 28 cases of lymph node non-metastatic BC tissues 194 cases of BC tissues and 59 cases of normal tissues | Up-regulation of CDK3 in primary tumor tissues | _ | _ | _ | [181] |
30 PTANCT | Up-regulation of HuR and CDK3 | _ | _ | chemoresistance | [187] | |
37 PTANCT | Up-regulation of CDK3 and down of miR-125a-3p | _ | _ | _ | [183] | |
Colorectal cancer | 87 cases of PCC, 49 cases of MCC, and 52 cases of normal colon tissues | Up-regulation of CDK3 in MCC than PCC and in PCC than normal | _ | _ | TNM grade | [185] |
50 PTANCT | Up-regulation of circRNA_141539 (which regulated CDK3) | Shorter PFS | High levels of circRNA_141539 and low differentiation and stage III were found to be poor survival prognostic factors | TNM stage, T stage, and N stage, and negatively with histological grade | [186] | |
Hepatocellular carcinoma | GEO database (GSE22058: 96 PTANCT) 8 PTANCT | Down-regulation of miR-214/199a/199a* (which regulated CDK3) | Shorter OS | miR-214 expression was found to be an independent prognostic factor | _ | [189] |
Lung cancer | 31 PTANCT | Up-regulation of HuR (which regulated CDK3) | _ | _ | _ | [191] |
Nasopharyngeal carcinoma | 94 NPC tissues and 40 inflamed nasopharyngeal tissues | Up-regulation of CDK3 in NPC | _ | _ | infiltration, lymph node metastasis, tumor node metastasis, and TNM clinical staging | [192] |
Skin cancer | 65 tumor tissues and 9 normal tissues | Up-regulation of NFAT3 | _ | _ | CDK3 levels were positively associated with both NFAT3 and phosphorylated NFAT3-Ser259 | [193] |